Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment

While encountering the Coronavirus disease 2019 (COVID-19) outbreak, yet, there are no specific available drugs against SARS-CoV-2 infection. Hence, the administration of repurposed medications could be one of the most promising strategies to fight the pathogenic disease. This chapter aimed to represent the ongoing clinical trials, and the potent therapeutics and medications used for inhibiting SARS-CoV-2 infection with respect to their targets and mechanism of action. In order to inhibit the virus, enhance or modulate the immune system, manage the deregulated inflammatory responses, and control the symptoms, several antivirals such as remdesivir, favipiravir, lopinavir/ritonavir, umifenovir, and ribavirin alongside interferons, convalescent plasma, interleukin inhibitors, anticitokines and immunosuppressant drugs, corticosteroids, antibiotics, anticoagulants, natural medicine, recombinant proteins, and monoclonal antibodies have been employed either alone or in combination to combat COVID-19.